<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620641</url>
  </required_header>
  <id_info>
    <org_study_id>35647</org_study_id>
    <nct_id>NCT05620641</nct_id>
  </id_info>
  <brief_title>Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Comparative Clinical Study Among Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the possible efficacy of ondansetron and gabapentin on&#xD;
      postoperative nausea and vomiting in patient with morbid obesity who will undergo&#xD;
      laparoscopic sleeve gastrectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a double blind randomized, controlled, parallel, study. A total of1 00&#xD;
      morbidly obese patients who will be scheduled for sleeve gastrectomy will be included in the&#xD;
      study. The patients will be selected from those attending Gastrointestinal and Laparoscopic&#xD;
      Surgery Unit, General Surgery Department, Tanta University Hospital, Tanta, Egypt. The&#xD;
      participants will be randomized into two groups by closed envelop method,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2022</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of this study will be the complete response within the first 48 h after surgery.</measure>
    <time_frame>The first 48 hours after surgery.</time_frame>
    <description>Complete response is defined as the absence of PONV and the lack of a need for rescue antiemetic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the level of the biological parameter vasopressin</measure>
    <time_frame>The first 48 hours after surgery.</time_frame>
    <description>5 ml of venous blood will be withdrawn from each participant by antecubital venipuncture. Blood samples will be centrifuged at 3000 rpm for 15 min to separate sera. Sera will be kept at deep freeze (-80°C) until analysis of serum concentrations of vasopressin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of the biological parameter dopamine</measure>
    <time_frame>The first 48 hours after surgery.</time_frame>
    <description>5 ml of venous blood will be withdrawn from each participant by antecubital venipuncture. Blood samples will be centrifuged at 3000 rpm for 15 min to separate sera. Sera will be kept at deep freeze (-80°C) until analysis of serum concentrations of dopamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of the biological parameter substance p</measure>
    <time_frame>The first 48 hours after surgery.</time_frame>
    <description>5 ml of venous blood will be withdrawn from each participant by antecubital venipuncture. Blood samples will be centrifuged at 3000 rpm for 15 min to separate sera. Sera will be kept at deep freeze (-80°C) until analysis of serum concentrations of substance p</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of the biological parameter Serotonin</measure>
    <time_frame>The first 48 hours after surgery.</time_frame>
    <description>5 ml of venous blood will be withdrawn from each participant by antecubital venipuncture. Blood samples will be centrifuged at 3000 rpm for 15 min to separate sera. Sera will be kept at deep freeze (-80°C) until analysis of serum concentrations of Serotonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of the biological parameter Tachykinin 1</measure>
    <time_frame>The first 48 hours after surgery.</time_frame>
    <description>5 ml of venous blood will be withdrawn from each participant by antecubital venipuncture. Blood samples will be centrifuged at 3000 rpm for 15 min to separate sera. Sera will be kept at deep freeze (-80°C) until analysis of serum concentrations of Tachykinin 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Post Operative Nausea and Vomiting</condition>
  <condition>Sleeve Gastrectomy</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>include 50 patients scheduled for sleeve gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>include 50 patients scheduled for sleeve gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 8mg</intervention_name>
    <description>50 patients will receive intravenous ondansetron 8 mg before the end of surgery.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both male and female patients will be included.&#xD;
&#xD;
          -  Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥35 kg/m2 with the&#xD;
             presence of comorbidity such as hypertension, arthritis, and diabetes.&#xD;
&#xD;
          -  Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥ 40 kg/m2 without&#xD;
             comorbidity.&#xD;
&#xD;
          -  Patients fit for anesthesia and surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patients with BMI &gt;55 kg/m2.&#xD;
&#xD;
          -  Patients with previous procedures for the treatment of obesity.&#xD;
&#xD;
          -  Pregnant females and lactating women.&#xD;
&#xD;
          -  Patients with psychological or psychiatric disease&#xD;
&#xD;
          -  Administration of antiemetic medication or systemic corticosteroids within 24 hours&#xD;
             before surgery&#xD;
&#xD;
          -  Patients who experienced vomiting within 24 hours before surgery.&#xD;
&#xD;
          -  Patients with history of alcohol or drug abuse.&#xD;
&#xD;
          -  Patients with hypersensitivity or contraindications to any of the drugs used in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aya Moussa, assistant lecturer</last_name>
    <phone>01222607803</phone>
    <email>aya.mosa@pharm.tanta.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>tarek mostafa, professor</last_name>
    <phone>01154594035</phone>
    <email>Toulouse1985@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastrointestinal and Laparoscopic Surgery Unit, General Surgery Department, Tanta University Hospital, Tanta, Egypt</name>
      <address>
        <city>Tanta</city>
        <state>Gharbiya</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Aya Gamal Moussa</investigator_full_name>
    <investigator_title>Assistant Lecturer at Clinical Pharmacy department , Faculty of Pharmacy -Tanta University</investigator_title>
  </responsible_party>
  <keyword>Postoperative Nausea and Vomiting</keyword>
  <keyword>Laparoscopic Sleeve Gastrectomy</keyword>
  <keyword>ondansetron</keyword>
  <keyword>gabapentine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

